Toxic Effects Induced by Curcumin in Human Astrocytoma Cell Lines
Overview
Authors
Affiliations
Objective: The objective of this study was to describe the toxicity induced by curcumin in human astrocytoma cell lines.
Methods: The effects induced by curcumin, at 100 µM for 24 h, were evaluated in four astrocytoma cell lines using crystal violet assay and through the evaluation of morphological and ultrastructural changes by electron microscopy. Also, the results of vital staining with acridine orange and propidium iodide for acidic vesicles and apoptotic bodies were analyzed and the expression of the Beclin1 gene was assessed by RT-PCR.
Results: The cells treated with curcumin at 100 µM induced an inhibitory concentration50 of viability with morphological changes characterized by a progressive increase in large, non-acidic vesicles devoid of cytoplasmic components and organelles, but that conserved the cell nuclei. No DNA breakage was observed. The astrocytoma cells showed no apoptosis, necrosis or autophagy. Expression of BECLIN1 was not induced (p < 0.05) by curcumin in the astrocytoma cells.
Conclusions: Curcumin at 100 µm induced a new type of death cell in astrocytoma cell lines.
Garcia-Lopez D, Zaragoza-Ojeda M, Eguia-Aguilar P, Arenas-Huertero F Int J Mol Sci. 2024; 25(7).
PMID: 38612890 PMC: 11012637. DOI: 10.3390/ijms25074078.
The Anti-Cancer Effect of Four Curcumin Analogues on Human Glioma Cells.
Luo S, Wu Y, Huang L, Huang S, Hueng D Onco Targets Ther. 2021; 14:4345-4359.
PMID: 34376999 PMC: 8349541. DOI: 10.2147/OTT.S313961.
Exploring Sonic Hedgehog Cell Signaling in Neurogenesis: Its Potential Role in Depressive Behavior.
Rana T, Behl T, Sehgal A, Sachdeva M, Mehta V, Sharma N Neurochem Res. 2021; 46(7):1589-1602.
PMID: 33786718 DOI: 10.1007/s11064-021-03307-z.
Montiel-Davalos A, Silva Sanchez G, Huerta-Garcia E, Rueda-Romero C, Soca Chafre G, Mitre-Aguilar I PLoS One. 2017; 12(12):e0188169.
PMID: 29244817 PMC: 5731739. DOI: 10.1371/journal.pone.0188169.
Pouliquen D, Nawrocki-Raby B, Nader J, Blandin S, Robard M, Birembaut P Oncotarget. 2017; 8(34):57552-57573.
PMID: 28915695 PMC: 5593667. DOI: 10.18632/oncotarget.15744.